Core Insights - The Chinese biomanufacturing industry is projected to reach a scale of 1.01 trillion yuan in 2024, with a year-on-year growth of 15.4%. By 2030, the industry is expected to exceed 2.5 trillion yuan, with a compound annual growth rate of 16.8% [1]. Group 1: Industry Overview - The DT New Materials Research Institute has been actively monitoring and supporting the progress and innovation in the synthetic biology sector since the release of the "China Synthetic Biology Industry Map (2023)" which includes over 300 listed companies [1]. - The upcoming "4th Synthetic Biology and Green Biomanufacturing Conference (SynbioCon 2025)" will take place from August 20-22 in Ningbo, Zhejiang, where the "China Synthetic Biology Industry Distribution Map (2025 Edition)" will be announced, featuring over 500 representative biomanufacturing companies and their product information [1][9]. Group 2: Event Details - The conference will focus on five key areas: AI + Biomanufacturing, Green Chemistry and New Materials, Future Food, Future Agriculture, and Beauty Raw Materials, inviting industry leaders, experts, and various stakeholders to explore trends in biomanufacturing development during the 14th Five-Year Plan [9]. - Participants at the conference can receive a free copy of the industry map valued at 499 yuan, and eligible biomanufacturing companies can register to be included in the map [6][10].

Core Insights - The article highlights the rapid development and innovation in China's synthetic biology sector, particularly focusing on Shanghai as a leading hub for synthetic biology initiatives and projects [2][3][4]. Group 1: Industry Development - Shanghai is recognized as the primary force in China's synthetic biology development, with significant milestones such as the establishment of the Chinese Academy of Sciences' synthetic biology laboratory in 2008 [2]. - In 2023, Shanghai released an action plan to accelerate synthetic biology innovation and build a high-end biomanufacturing industry cluster from 2023 to 2025 [2]. - The Shanghai Municipal Science and Technology Commission has initiated key projects in synthetic biology and computational biology to support rapid industry growth [2]. Group 2: Funding and Support - Shanghai has allocated substantial funding for synthetic biology projects, including 42 million yuan for 18 projects and 37 million yuan for 16 projects [3]. - The city has established industrial clusters in areas like Zhangjiang Science City and Lingang New Area, providing comprehensive support from research and development to pilot testing [3]. Group 3: Notable Companies - A total of 66 representative companies from Shanghai have been listed in the "China Biomanufacturing 500+ Representative Enterprises List" based on their team, core products, and competitive potential [4]. - Key companies in the synthetic biology sector include Kasei Biotech, Enkasei Pharmaceutical, and Changjin Biotech, all of which are located in the aforementioned industrial parks [3][4]. Group 4: Upcoming Events - The Fourth Synthetic Biology and Green Biomanufacturing Conference will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and biomanufacturing, green chemicals, new materials, future food, and agriculture [19][21]. - The conference aims to gather international enterprises, industry experts, and government representatives to explore trends and innovations in the biomanufacturing sector [19].

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The chemical sector's overall performance ranked 11th this week, with a change of +1.77%, outperforming the Shanghai Composite Index by 1.08 percentage points and underperforming the ChiNext Index by 1.40 percentage points [4] - The chemical industry is expected to continue its trend of differentiated performance in 2025, with recommendations to focus on synthetic biology, pesticides, chromatography media, sugar substitutes, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] - The supply of third-generation refrigerants is entering a high prosperity cycle due to quota policies, with demand remaining stable amid market expansion [5] - The electronic specialty gases market presents significant domestic substitution opportunities due to high technical barriers and increasing demand from semiconductor, display, and photovoltaic sectors [6][8] - The trend of light hydrocarbon chemicals is becoming global, with a shift towards lighter raw materials for olefin production, which is expected to lead to a revaluation of leading companies in this sector [8] - The MDI market is characterized by oligopoly, with a favorable supply structure expected as demand gradually recovers [12] Summary by Sections Industry Review - The chemical sector's performance for the week of July 14-18, 2025, showed a rise of 1.77%, ranking 11th among sectors [22] - The top three performing sub-sectors were synthetic resins, membrane materials, and polyurethanes, while the bottom three were oil product trading, compound fertilizers, and organic silicon [24] Supply Side Tracking - A total of 155 companies in the chemical industry had their production capacities affected this week, with 1 new shutdown and 7 restarts reported [14] Key Industry Dynamics - A fire at Covestro's plant in Germany led to supply disruptions for key products, including TDI, due to a chlorine supply interruption [35] - The Ministry of Industry and Information Technology announced upcoming growth stabilization plans for ten key industries, including petrochemicals [35]

Core Viewpoint - The article highlights the upcoming SynBioCon 2025 event, focusing on the potential of synthetic biology and biomanufacturing, showcasing innovative research teams, technologies, and products in the field [2][5][14]. Group 1: Event Overview - The SynBioCon 2025 will take place from August 20-22 in Ningbo, Zhejiang, featuring a special session called the "Biomanufacturing Youth Forum" with nearly 30 presentations [2][10]. - The event aims to facilitate the exchange of innovative research outcomes and promote collaboration between researchers and industry stakeholders [2][14]. Group 2: Forum Details - The Youth Forum will include presentations from various universities and research institutions, such as Anhui University of Technology and South China University of Technology [4][5]. - The forum is designed to help attendees understand key scientific issues, solutions, and future development directions in biomanufacturing within a 15-minute format [3][14]. Group 3: Special Activities - A closed-door high-level seminar will discuss the trends and growth points of biomanufacturing as part of the event's agenda [11]. - The event will also feature project roadshows and technology showcases, inviting participation from leading parks and investment institutions [14][20]. Group 4: Thematic Discussions - The conference will cover various topics, including green chemicals, new materials, AI in biomanufacturing, and future food and agriculture [15][17][19]. - Specific focus areas include the development of bio-based materials, non-grain carbon source utilization, and the application of AI in enhancing biomanufacturing processes [18][22].

这项研究在国际上实现了Mb尺度人类基因组的从头合成组装、跨物种转移与功能重塑。SynNICE方法 具有双重价值：首次揭示了合成基因组在进入受体细胞后被细胞环境识别和重塑的过程，为研究表观遗 传修饰的的从头建立提供了全新的技术手段；为染色体异常相关疾病的治疗开辟了新思路，未来有望发 展出针对染色体疾病的创新性治疗方案，并推动其向临床应用转化。 链接 自21世纪初"人类基因组计划"完成人类染色体测序以来，研究人员便开始追求"从头书写"基因组的能 力。基因组合成有助于揭示人类基因组的DNA序列与功能之间的因果关系，从利用测序技术"读取"遗 传信息，到主动地"编写"生命密码，有望在生物医药、人类遗传性疾病的治疗等领域开辟变革性的应用 前景。我国在基因组合成领域进行了超前布局，2015年天津大学元英进团队成功完成了酿酒酵母5号和 10号两条染色体的化学合成，开发了高效的染色体缺陷靶点定位和精准修复技术，相关研究成果于2017 年发表在《科学》期刊后，就致力于突破人类基因组合成的关键技术。 为染色体异常相关疾病治疗开辟新思路 中化新网讯 7月10日，中国化工报记者从天津大学了解到，该校合成生物与生物制造学院元英进院士团 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing global biotechnology revolution, emphasizing its integration into economic and social development, addressing major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [1] - The Huazhong Securities Synthetic Biology Index, which includes 58 companies involved in synthetic biology and related technologies, decreased by 2.50% to 1484.292 during the week of June 30 to July 4, 2025, underperforming compared to the Shanghai Composite Index and the ChiNext Index [2][14] Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector experienced a decline of 2.50%, ranking 32nd among various sectors during the week of June 30 to July 4, 2025 [14] 1.2 Company Business Progress - Meihua Biological completed an overseas acquisition for HMO and high-end amino acid production, with a transaction value of approximately 8.33 billion yuan [21] - Weiyuan Biological's alolose sugar received approval as a new food ingredient, becoming the first company in China to produce it through fermentation technology [21] - Jinbo Biological secured a 3.4 billion yuan investment from Yangshengtang and Hangzhou Jiushi, enhancing its R&D capabilities in collagen technology [22] - Avantium signed a supply agreement for fully plant-based PEF packaging materials, emphasizing sustainability [24] - Syzygy Plasmonics announced the launch of a sustainable aviation fuel facility, aiming to produce over 350,000 gallons annually [24] 1.3 Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly a hundred firms completing new rounds of funding since the beginning of 2025. Zhejiang Rongrui Technology raised nearly 100 million yuan in a Pre-A round [27][28]

Core Viewpoint - Synthetic biology aims to "synthesize and design life," with significant advancements in genome synthesis and assembly, particularly in higher organisms, despite facing challenges related to repetitive sequences and cross-species DNA transfer [1][2]. Group 1: Technological Breakthroughs - Tianjin University's team achieved the first precise assembly and cross-species delivery of megabase-scale human DNA, marking a significant milestone in synthetic biology [2]. - The newly developed SynNICE technology enables the precise assembly of highly repetitive human genomic sequences in yeast and facilitates the efficient transfer of synthetic DNA into mouse embryos [3][5]. Group 2: Research Findings - The study successfully demonstrated de novo DNA methylation patterns in mouse embryos, indicating that the synthetic genome can be recognized and modified by the host cell environment [5][7]. - A hierarchical assembly strategy was employed to synthesize a 1.14 Mb region of the human Y chromosome, which is crucial for understanding male infertility [3][7]. Group 3: Implications for Disease Treatment - The research opens new avenues for treating chromosomal abnormalities and could lead to innovative therapeutic strategies for related diseases [7][9]. - The potential for using genetically modified pigs as organ donors for humans could be enhanced, addressing the global organ shortage issue by improving the longevity of transplanted organs [9][10]. Group 4: Future Prospects - The SynNICE technology platform is expected to facilitate large-scale genomic modifications, potentially transforming organ transplantation practices and enhancing the understanding of genetic diseases [11][12]. - The advancements in synthetic genome assembly and transfer techniques are anticipated to propel the field of synthetic biology forward, providing new models for studying epigenetic modifications and chromosomal disorders [10][11].

Core Viewpoint - The establishment of Huaxi Tang'an Bio-Tech in Guangming Science City marks a significant strategic deployment for Huaxi Bio, expanding its diversification beyond hyaluronic acid and establishing a global non-animal heparin full industry chain platform in the Guangdong-Hong Kong-Macao Greater Bay Area [1][3]. Group 1: Company Development - Huaxi Bio focuses on synthetic biology, emphasizing glycomics and cell biology, and has developed four major business segments: bioactive raw materials, pharmaceuticals and medical devices, skin science innovation, and nutritional science innovation [1]. - Huaxi Tang'an has achieved multi-dimensional technological breakthroughs in the field of enzyme-synthesized heparin, with applications in cosmetics, pharmaceuticals, and medical devices, particularly in preventing and treating thromboembolic diseases and cardiovascular surgeries [1][3]. Group 2: Industry Collaboration and Ecosystem - The signing ceremony involved partnerships with Guangming District, the National Bio-Manufacturing Industry Innovation Center, and private equity funds, leveraging policy and resource advantages to accelerate project development [3]. - Guangming District has attracted over 130 companies in the synthetic biology sector, with an estimated industry valuation of nearly 40 billion, establishing a comprehensive innovation ecosystem covering research, technology development, and talent support [3][4]. Group 3: Future Prospects - The establishment of Huaxi Tang'an is expected to attract more upstream and downstream enterprises in the medical beauty and cosmetics sectors, contributing to the creation of a distinctive industrial cluster in Guangming [4].

Core Viewpoint - The article highlights the upcoming Synbio China 2025 event, focusing on the integration of scientists, entrepreneurs, and investors in the field of synthetic biology, emphasizing its strategic importance for the development of China's bio-economy [33]. Event Details - The Synbio China 2025 event will take place on August 1-2, 2025, at the Suzhou International Expo Center, alongside the 7th CMC-China Expo [1]. - Confirmed attendees include experts from various universities such as Beijing University of Chemical Technology, Shanghai Jiao Tong University, and East China University of Science and Technology, as well as representatives from companies like Micro Factory and Henan Biological Industry Group [2]. Agenda Highlights - The agenda includes lectures from academicians and experts, covering topics such as the opportunities and challenges in the industrialization of synthetic biology, and innovative pathways for non-grain biomass potential [6][7]. - Specific sessions will focus on enabling technologies, including enzyme engineering and CRISPR/Cas9 applications, as well as the development of bio-based materials and their industrial applications [8][10]. Industry Challenges - The article discusses the rapid dissemination of synthetic biology concepts in China, while also addressing challenges such as achieving scalable production, realizing the value of synthetic biological products, and fostering innovation in core competitiveness [33]. Networking Opportunities - The event aims to facilitate face-to-face interactions among founders, industry experts, investors, and government representatives, providing a platform for project promotion and industry guidance [35]. Participation and Registration - Attendees are encouraged to register for free through a QR code provided in the article, ensuring access to the event and its networking opportunities [4][12]. Additional Information - The 7th CMC-China Expo is expected to attract around 20,000 participants, featuring 450 exhibiting companies and 600 invited guests, with multiple forums dedicated to cutting-edge topics in the industry [79].

Core Viewpoint - Zhejiang Province is accelerating the innovation and development of the synthetic biology industry, aiming for a total industry scale of 150 billion by 2027, with core enterprises achieving a production value of 20 billion [1][2]. Group 1: Industry Development Plan - The "Implementation Plan for Accelerating the Innovation and Development of the Synthetic Biology Industry in Zhejiang Province" outlines six major development directions, eleven regional industrial layouts, key tasks for nine universities and research institutes, and ten core technology breakthroughs [1][2]. - The plan aims to establish an internationally influential synthetic biology industry innovation development hub in Zhejiang [1]. Group 2: Alliance Formation - The Zhejiang Synthetic Biology Industry Technology Alliance, guided by the Zhejiang Provincial Department of Economy and Information Technology, is a non-profit organization initiated by Zhejiang University Hangzhou International Innovation Center, aiming to promote technological innovation and industry cultivation [2]. - The alliance will leverage the advantages of Zhejiang University in talent cultivation, technological innovation, and high-level platforms to support the synthetic biology industry [2]. Group 3: Research and Development Facilities - The Zhejiang University Hangzhou International Innovation Center has established the Bio and Molecular Manufacturing Research Institute and the iBioFoundry, the largest and most integrated automated high-throughput scientific device in the field globally [4]. - This facility enables full-process automation from sample intelligent access to product detection and is now open as a shared research platform for teams and enterprises [4]. Group 4: Upcoming Conference - The 2025 Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on AI and biological manufacturing, as well as four application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials [6][8]. - The conference aims to explore the development trends of the bio-manufacturing industry and promote the transfer and transformation of scientific and technological achievements [6].